Grifols (NASDAQ:GRFS - Get Free Report) is expected to be announcing its earnings results on Wednesday, February 26th. Analysts expect the company to announce earnings of $0.13 per share and revenue of $1.86 billion for the quarter.
Grifols Price Performance
GRFS stock traded down $0.08 during trading on Friday, hitting $7.45. 562,369 shares of the company's stock traded hands, compared to its average volume of 774,833. The business has a fifty day simple moving average of $7.38 and a two-hundred day simple moving average of $8.08. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.79 and a current ratio of 2.26. Grifols has a 1 year low of $5.30 and a 1 year high of $9.96.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on GRFS shares. Berenberg Bank raised shares of Grifols to a "strong-buy" rating in a report on Tuesday, October 29th. Morgan Stanley assumed coverage on shares of Grifols in a report on Wednesday, February 12th. They issued an "overweight" rating on the stock.
Check Out Our Latest Report on Grifols
Grifols Company Profile
(
Get Free Report)
Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease.
Read More
Before you consider Grifols, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grifols wasn't on the list.
While Grifols currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
